Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387803 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation
A Phase 2 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 581
- Enrollment target
NCT00387803: Completed Phase 2 study, sponsored by Boston Scientific Corporation.
NCT00387803 is a Phase 2 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 581 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (337% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00387803, a Phase 2 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 581 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if cardiac resynchronization therapy when combined with defibrillation is safe and effective in the treatment of symptomatic heart failure.
Interventions
- DEVICE Cardiac Resynchronization Therapy with Defibrillation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 581 participants |
| Start Date | 1998-02 |
| Est. Completion | 2001-08 |
| Phase | Phase 2 |
What the finished NCT00387803 record still lists
NCT00387803 is an interventional study that assigns participants to a tested intervention. The registered 581 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (337% higher).
The record links to 0 conditions, and to 1 intervention - of which Cardiac Resynchronization Therapy with Defibrillation is the first listed.
NCT00387803 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00387803 about?
NCT00387803 is a clinical study titled "Safety and Effectiveness of Cardiac Resynchronization Therapy With Defibrillation". The purpose of this study was to determine if cardiac resynchronization therapy when combined with defibrillation is safe and effective in the treatment of symptomatic heart failure.
What is the current status of trial NCT00387803?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 581 participants. The study started on 1998-02. Estimated completion is 2001-08.
What interventions are being tested in trial NCT00387803?
The interventions under investigation include: Cardiac Resynchronization Therapy with Defibrillation (DEVICE).
Who is sponsoring clinical trial NCT00387803?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00387803's enrollment target sits among peer trials
581 58th of 2000 higher than 1,943 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06350097 · 582 participants · Phase 3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- NCT06563895 · 582 participants · Phase 3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- NCT06819007 · 582 participants · Phase 3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia